Published in Women's Health Weekly, August 26th, 2004
"Darifenacin is a muscarinic antagonist in Phase III clinical trials for the treatment of overactive bladder (OAB). Darifenacin demonstrates relative selectivity for the M-3 muscarinic receptor subtype over the M-1 and M-2 subtypes. In clinical trials, darifenacin has been compared to placebo for the treatment of symptoms of OAB in adult men and women," investigators in the United States report.
"Patients treated with darifenacin experienced significantly greater reductions in the number of incontinence episodes per week,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.